Israel: A new study published in JAMA Network Open highlights a key safety insight for patients with type 2 diabetes taking ...

A study found that the newer generation of much more effective diabetes medications are reaching only a fraction of the ...

After the SGLT2 inhibitors were shown to benefit patients with type 2 diabetes, reducing cardiovascular events, including hospitalization for heart failure, the next natural research question ...

A UCSF analysis has found that the newer generation of much more effective diabetes medications are reaching only a fraction ...

SGLT2 inhibitors have become a major drug used to treat diabetes, heart failure, and chronic kidney disease. However, there have been questions as to whether it is safe to use these drugs in ...

A study published in JAMA Surgery involving nearly 500,000 surgeries among U.S. veterans found that patients taking SGLT2 ...

A UC San Francisco analysis has found that the newer generation of much more effective diabetes medications are reaching only ...

Smartphone-based home screening significantly boosts chronic kidney disease (CKD) diagnosis and follow-up care, enhancing ...

GLP-1 receptor agonist users had a significant 39% higher risk of requiring KRT (95% CI, 1.19-1.63) compared with SGLT2 inhibitor users, Dr Chang’s team reported in the American Journal of ...

Some health-obsessed Americans believe the next antiaging therapeutic already exists—in the medicine cabinets of millions of diabetes patients. The widely used class of drugs, called SGLT2 ...

Heerspink said future studies should evaluate clinical outcomes with longer-term use of finerenone plus an SGLT2 inhibitor. Reference: Agarwal R. Session ID S 0.1.